Edgar Filing: BAFFI ROBERT - Form 4

BAFFI ROF Form 4 January 07, FORN Check th if no lon subject to Section Form 4 Form 5 obligation may cons <i>See</i> Instru 1(b).	2013 A 4 UNITED nis box iger o 16. or Filed pur Section 17(STATES SECU: Wa IENT OF CHAN suant to Section a) of the Public U 30(h) of the I	Ishington NGES IN SECUI 16(a) of th Jtility Hol	, D.C. 20 BENEFI RITIES ne Securit ding Com	549 CIA ies E ipany	L OWN	NERSHIP OF e Act of 1934, 1935 or Sectior	OMB Number: Expires: Estimated a burden hour response	0	
BAFFI ROBERT Sy B			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(3. Date of Earliest Transaction (Month/Day/Year) 01/03/2013				Director 10% Owner X Officer (give title Other (specify below) below) EVP, Technical Operations			
NOVATO,	endment, Date Original onth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 					
(City)	(State)	(Zip) Tab	le I - Non-l	Derivative	Securi	ities Acqu	uired, Disposed of	, or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transacti Code (Instr. 8) Code V	4. Securit or(A) or Dis (Instr. 3, 4)	sposed	l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	01/03/2013(1)	01/03/2013	М	20,000	Α	\$ 17.54	120,413	D		
Common Stock	01/03/2013 <u>(1)</u>	01/03/2013	S	20,000	D	\$ 53	100,413	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: BAFFI ROBERT - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amour or Numbe of Shar
Stock Option (right to buy) Common Stock	\$ 17.54	01/03/2013 <u>(1)</u>	01/03/2013	М		20,000	05/20/2007 <u>(2)</u>	11/19/2016	Common Stock	20,00

Reporting Owners

Reporting Owner Name / Address		Relationships						
1 0	Director	10% Owner	Officer	Other				
BAFFI ROBERT C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			EVP, Technical Operations					
Signatures								
/s/ Laura Randall Woodhead, Attorney-in-Fact	01/0	7/2013						
**Signature of Reporting Person	D	ate						
Explanation of Responses								

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 plan executed on August 6, 2012.

(2) Options vest on May 20, 2007 and 1/48th on the 20th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.